[Long-Term Elderly Survivor with Recurrent MSI-High Gastric Cancer Using Pembrolizumab as a Second-Line Chemotherapy]

Satoshi Hamada; Shuhei Komatsu; Mizuki Nishiko; Tomoki Konishi; Daiki Matsubara; Koji Soga; Katsumi Shimomura; Jun Ikeda; Fumihiro Taniguchi; Yasuhiro Shioaki

[Long-Term Elderly Survivor with Recurrent MSI-High Gastric Cancer Using Pembrolizumab as a Second-Line Chemotherapy]

Gan To Kagaku Ryoho. 2022 Jan;49(1):83-84.

[Article in Japanese]

Authors

Satoshi Hamada¹, Shuhei Komatsu, Mizuki Nishiko, Tomoki Konishi, Daiki Matsubara, Koji Soga, Katsumi Shimomura, Jun Ikeda, Fumihiro Taniguchi, Yasuhiro Shioaki

Affiliation

¹ Dept. of Surgery, Kyoto First Red Cross Hospital.

PMID: 35046369

Abstract

KEYNOTE-158 and 061 trials revealed the efficacy and safety of pembrolizumab(KEYTRUDA®)treatment in patients with recurrent high microsatellite instability(MSI-high)gastric cancer following gastrectomy. Here, we successfully treated an elderly case with recurrences following radical gastrectomy for advanced gastric cancer using pembrolizumab as a second- line chemotherapy. Even in elderly patients, pembrolizumab might contribute to effective and safe treatment in late-line chemotherapy for recurrent MSI-high gastric cancer.

MeSH terms

Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Microsatellite Instability*
Neoplasm Recurrence, Local / drug therapy
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / surgery
Survivors

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab